Efficacy and Safety of Dulaglutide by Baseline HbA1c in Chinese Patients with Type 2 Diabetes: A Post Hoc Analysis

MLA

Hai Ya Wu, et al. “Efficacy and Safety of Dulaglutide by Baseline HbA1c in Chinese Patients with Type 2 Diabetes: A Post Hoc Analysis.” Diabetes Therapy, vol. 11, Apr. 2020, pp. 1147–59. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....78ec129dbbd6d1fd121dcbfabc4d69a0&authtype=sso&custid=ns315887.

APA

Hai Ya Wu, Miao Yu, Xiao Feng Lv, Guo Yue Yuan, & Bin Zhang. (2020). Efficacy and Safety of Dulaglutide by Baseline HbA1c in Chinese Patients with Type 2 Diabetes: A Post Hoc Analysis. Diabetes Therapy, 11, 1147–1159.

Chicago

Hai Ya Wu, Miao Yu, Xiao Feng Lv, Guo Yue Yuan, and Bin Zhang. 2020. “Efficacy and Safety of Dulaglutide by Baseline HbA1c in Chinese Patients with Type 2 Diabetes: A Post Hoc Analysis.” Diabetes Therapy 11 (April): 1147–59. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....78ec129dbbd6d1fd121dcbfabc4d69a0&authtype=sso&custid=ns315887.